Join us on Thursday, January 14^th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Epizyme Inc, Incyte Corporation, Karyopharm Therapeutics, Novartis, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Seagen Inc.

Thursday, January 14, 2021
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

MODULE 1: Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

• Appropriate integration of obinutuzumab into current algorithms for treatment-naïve and relapsed/refractory (R/R) FL; potential benefit in preventing early disease progression
• Results and clinical implications of Phase III studies evaluating the “R-squared” regimen of lenalidomide/rituximab for newly diagnosed and R/R FL
• Similarities and differences among available PI3 kinase inhibitors; available research data and optimal selection in the management of FL
• Mechanism of action, efficacy and tolerability of tazemetostat in patients with previously treated FL; recent FDA approval and current clinical role for FL with and without EZH2 mutations
• Available data documenting the safety and efficacy of chimeric antigen receptor (CAR) T-cell therapy for patients with FL; FDA regenerative medicine advanced therapy designation for tisagenlecleucel for R/R disease
• Research database supporting the FDA approvals of ibrutinib, acalabrutinib and zanubrutinib for R/R MCL; available activity and safety data and ongoing Phase III investigation for previously untreated disease
• Available data with, current clinical role of and ongoing trials assessing venetoclax alone or combined with other agents for patients with MCL
• Design, eligibility criteria and available safety and efficacy findings from studies evaluating CAR T-cell therapy for R/R MCL
• FDA approval of brexucabtagene autoleucel and optimal integration into MCL treatment algorithms

MODULE 2: Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma (HL) and T-Cell Lymphoma

• Longer-term follow-up from clinical trials evaluating the efficacy and safety of axi-cel (axicabtagene ciloleucel), tis-cel (tisagenlecleucel) and liso-cel (lisocabtagene maraleucel) for DLBCL; identification of patients appropriate for CAR T-cell therapy
• FDA approval of polatuzumab vedotin for patients with R/R DLBCL; optimal incorporation into management algorithms and ongoing investigation in the up-front setting
• Design, eligibility criteria and efficacy and safety findings from the Phase IIb SADAL trial evaluating selinexor for patients with R/R DLBCL; recent FDA approval and optimal integration into clinical practice
• Tafasitamab: Mechanism of action, key efficacy and safety findings (eg, L-MIND, Re-MIND trials) and FDA priority review status for tafasitamab/lenalidomide for patients with R/R DLBCL
• Activity and safety of and development plans for the bispecific antibody mosunetuzumab for patients with poor-prognosis B-cell non-Hodgkin lymphomas
• Long-term follow-up from the Phase III ECHELON-1 trial comparing brentuximab vedotin (BV) in combination with doxorubicin/vinblastine/dacarbazine (AVD) to ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) for patients with previously untreated advanced classical HL; role of BV/AVD as first-line therapy
• Available activity and safety data with and ongoing evaluation of immune checkpoint inhibitors alone or in combination with other systemic approaches (eg, chemotherapy, BV) for patients with newly diagnosed or R/R HL
• Appropriate utilization of BV in combination with chemotherapy for previously untreated CD30-expressing peripheral T-cell lymphoma

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of lymphomas.

Learning Objectives
Upon completion of this activity, participants should be able to

• Evaluate patient- and disease-specific factors when designing an optimal induction therapeutic approach for patients with newly diagnosed follicular lymphoma (FL) requiring active therapy.
• Appreciate the FDA approval of rituximab/lenalidomide for the management of relapsed/refractory (R/R) FL and available Phase III data investigating its use as front-line therapy, and optimally incorporate this novel approach into current treatment algorithms.
• Compare and contrast the data supporting the efficacy of the commercially available PI3K inhibitors idelalisib, copanlisib and duvelisib to optimally integrate these agents into the care of patients with R/R FL.
• Recognize the recent FDA approval of tazemetostat for R/R FL, and identify patients for whom treatment with this novel agent may be appropriate.
• Describe the biologic rationale for, available data with and current clinical role of Bruton tyrosine kinase inhibitors for R/R mantle cell lymphoma (MCL), and discern how these agents can be appropriately and safely integrated into routine practice.
• Analyze the recent FDA approval of brexucabtagene autoleucel for patients with R/R MCL, and develop an understanding of how this novel therapy can be effectively used in practice.
• Assess the FDA-approved indications for polatuzumab vedotin and for selinexor in patients with R/R diffuse large B-cell lymphoma (DLBCL) after at least 2 prior therapies, and consider how these agents can be appropriately and safely incorporated into clinical management algorithms.
• Understand the mechanism of action of tafasitamab, and appreciate research data documenting the efficacy and safety of this novel anti-CD19 antibody in combination with lenalidomide for patients with R/R DLBCL.
• Review available efficacy and safety data with chimeric antigen receptor T-cell therapies directed at CD19, and identify patients with R/R large cell lymphomas for whom this approach may be appropriate.
• Consider clinical, biologic and patient-related factors in the selection of first-line therapy for patients with newly diagnosed classical Hodgkin lymphoma.
• Develop a long-term care plan for patients with R/R Hodgkin lymphoma, considering prior exposure to systemic therapy, eligibility for transplant, symptomatology, performance status and personal goals for treatment.
• Appraise the FDA approval of brentuximab vedotin as a component of first-line therapy for previously untreated CD30-expressing peripheral T-cell lymphomas, and optimally integrate this approach into routine clinical practice.
• Recall the design of ongoing clinical trials evaluating other novel investigational strategies for the treatment of Hodgkin and non-Hodgkin lymphomas, and counsel appropriately selected patients about availability and participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr Flowers — Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene, Celgene Corporation, Denovo Biopharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, MEI Pharma Inc, Pharmacyclics LLC, an AbbVie Company, Spectrum Pharmaceuticals Inc; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas, Celgene Corporation, Eastern Cooperative Oncology Group, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, National Cancer Institute, Pharmacyclics LLC, an AbbVie Company, Takeda Oncology, TG Therapeutics Inc, V Foundation for Cancer Research. Dr Smith — Consulting Agreements: Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, MorphoSys, TG Therapeutics Inc; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, Celgene Corporation, Epizyme Inc, Forty Seven Inc, Genentech, a member of the Roche Group, Karyopharm Therapeutics, Novartis, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, TG Therapeutics Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Epizyme Inc, Incyte Corporation, Karyopharm Therapeutics, Novartis, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Seagen Inc.